17.31  0.92 (5.61%)		08-10 16:00
Open: 16.27 High: 17.59 Volume: 999,444		Pre. Close: 16.39 Low: 16.27 Market Cap: 2,016(M)

Short term
Mid term
Targets	6-month :	22.1	1-year :	25.05
Resists	First :	18.92	Second :	21.45
Pivot price	16.32
Supports	First :	14.82	Second :	12.33
MAs	MA(5) :	16.34	MA(20) :	16.23
	MA(100) :	15.12	MA(250) :	13.65
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	24.6	D(3) :	20.2
RSI	RSI(14): 55.7
52-week	High :	21.45	Low :	9.81

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NVCR ] has closed below upper band by 30.3%. Bollinger Bands are 21.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	17.61 - 17.67	17.67 - 17.75
Low:	16.1 - 16.16	16.16 - 16.24
Close:	17.17 - 17.29	17.29 - 17.43

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Tue, 11 Aug 2026
First Trust Advisors LP Invests $1.03 Million in NovoCure Limited $NVCR - MarketBeat

Mon, 10 Aug 2026
NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued - simplywall.st

Mon, 10 Aug 2026
Dimensional Fund Advisors LP Buys 207,913 Shares of NovoCure Limited $NVCR - MarketBeat

Fri, 07 Aug 2026
Novocure Ltd (NVCR) Stock Analysis & Forecast - TradingKey

Fri, 31 Jul 2026
Novocure Stock Price Forecast. Should You Buy NVCR? - StockInvest.us

Fri, 24 Jul 2026
H.C. Wainwright cuts NovoCure stock price target to $32 on valuation - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	116 (M)
Shares Float	96 (M)
Held by Insiders	9.9 (%)
Held by Institutions	86.8 (%)
Shares Short	11,460 (K)
Shares Short P.Month	9,650 (K)

EPS	-1.3
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.9
Profit Margin	-21.3 %
Operating Margin	-5.8 %
Return on Assets (ttm)	-9.3 %
Return on Equity (ttm)	-43.3 %
Qtrly Rev. Growth	15.6 %
Gross Profit (p.s.)	4.58
Sales Per Share	6
EBITDA (p.s.)	-1.18
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	23 (M)

PE Ratio	-13.32
PEG Ratio	0
Price to Book value	5.96
Price to Sales	2.88
Price to Cash Flow	-717.35

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.